Navigation Links
Fifth Annual AACR Margaret Foti Award presented to Arthur D. Levinson, Ph.D.
Date:3/25/2011

ORLANDO, Fla. Arthur D. Levinson, Ph.D., chairman and former CEO of Genentech Inc., will receive the Fifth Annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 102nd Annual Meeting 2011, held April 2-6.

This award recognizes an individual whose leadership and extraordinary achievements in cancer research, or in support of cancer research, have made a major impact on the field.

"Dr. Levinson revolutionized the approach to developing cancer therapeutics, which led to targeted drugs," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "It is because of his scientific insight and inspirational leadership that we have gained advancements in drug development and personalized healthcare, benefitting countless cancer patients."

While working in the Princeton laboratory of Dr. Arnold J. Levine as a graduate student, Levinson identified adenovirus encoded antigens that were required for its tumorigenic ability. As a postdoctoral fellow in the laboratory of Drs. Mike Bishop and Harold Varmus at the University of California, San Francisco, Levinson discovered that the p60-Src protein was a membrane-associated phosphoprotein, and co-discovered it to be a protein kinase. This was the first description of an enzymatic activity to be associated with the product of an oncogene.

Levinson joined Genentech in 1980 as a senior scientist, and conducted research programs on oncogene function and mammalian gene expression. His lab provided formal proof that the src gene product was a tyrosine protein kinase. Other contributions to the research arena consisted of the demonstration that the ras gene product possessed intrinsic GTPase activity, whose activity is directly affected by mutations that activated the oncogenic potential of the gene. He also pioneered the development at Genentech of the first commercially efficient large-scale mammalian expression systems, now routinely used to produce therapeutic recombinant proteins.

As the leader of Genentech's R&D program, Levinson utilized a coordinated team approach, which led to the development of the cancer therapeutics Herceptin, Avastin and Rituxan. He also helped devise a systematic scientific approach to develop targeted biotherapeutics. An example of this approach involved the realization that implementing a diagnostic to classify breast cancer on the basis of HER2 expression would identify patients likely to respond to Herceptin. Though more commonplace now, at the time of this development it was a groundbreaking example of personalized healthcare.

Levinson joined Genentech, Inc. in 1980 as a research scientist. He was named senior vice president of research and development in 1993. He served as CEO from 1995 to 2009, and has been chairman of Genentech's board of directors since 1999. In 2010, Levinson was elected to the board of directors of Roche Holding Ltd.

Levinson serves on the board of scientific consultants of the Memorial Sloan-Kettering Cancer Center, on the industrial advisory board of the California Institute for Quantitative Biomedical Research, and on the advisory council for the Princeton University Lewis-Sigler Institute for Integrative Genomics. He is a director of Apple, Amyris Inc., NGM Biopharmaceuticals, and the Broad Institute of MIT and Harvard. Levinson previously served on the corporate board of Google, Inc.

Levinson is the recipient of numerous awards and honors, including the Irvington Institute's Corporate Leadership Award in Science, the National Breast Cancer Coalition's Corporate Leadership Award, Institutional Investor's Best Biotech CEO award, and Princeton University's James Madison Medal for a distinguished career in scientific research and in biotechnology. Barron's has repeatedly recognized Levinson as one of "The World's Most Respected CEOs." In 2008, he was elected as a fellow to the American Academy of Arts and Sciences.

Levinson has authored or co-authored more than 80 scientific articles and has been a named inventor on 11 U.S. patents. He was inducted into the Biotech Hall of Fame at the 2003 Biotech Meeting of chief executive officers.

Levinson received his Bachelor's of Science degree from the University of Washington in 1972. He conducted his graduate studies in biochemical sciences at Princeton University and received his doctorate in 1977.

The Fifth Annual AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research will be presented at the AACR 102nd Annual Meeting 2011 during the Opening Ceremony.


'/>"/>

Contact: Michele Sharp
Michele.Sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Women & Infants named Center of Excellence for Neonatal Care for fifth year
2. Vetted International Celebrates Their Fifth Anniversary
3. Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical
4. Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership
5. Women Should See Ob-Gyn Annually, Experts Say
6. American Academy of Orthopaedic Surgeons 2011 Annual Meeting tip sheet
7. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
8. Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award
9. The American Association for Cancer Research hosts its 102nd Annual Meeting
10. Mammography controversy to be explored at 19th Annual Congress on Womens Health
11. Only Half of Women Over 40 Get Annual Mammograms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... “ HEALING MIND : Five Steps to Ultimate Healing, Four Rooms ... teaches readers how to become their own therapist. Providing a useful step-by-step process for ... offers an understanding of how to heal one’s inner child using four archetypes of ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... (DMPG) will use the action analytics leader’s population health solutions, MDinsight® and ... clinical support to the Atlanta-area healthcare system. Details of the contract were not ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Registered nurses, ... free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, ... in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... Florida ... Bay Lightning take on the St. Louis Blues at the Amalie Arena. The puck ... portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA veteran franchise owner ... it’s the buildings of Nashville that will benefit. , “I’ve enjoyed being a part ... Nashville, there was no question that I would bring my business with me,” Bogacki ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
(Date:2/11/2016)... 2016  Governor Andrew M. Cuomo today announced a ... throughout Western New York . This ... Polytechnic Institute, includes a major expansion of Athenex,s North ... Buffalo , as well as the creation of ... Dunkirk . The combined projects are expected ...
Breaking Medicine Technology: